ClinicalTrials.gg
RecruitingNCT07764588ICE-AMIUpdated Aug 14, 2026

Innate Immune Cell Phenotypes and Early Fibrotic Repair in Acute Myocardial Infarction

An observational study in Myocardial Infarction, sponsored by Shanghai 10th People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Shanghai 10th People's Hospital · Observational

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 80 Years
Sex
All
01

Study summary

To determine the relationship of the phenotypes of neutrophils and monocytes with early fibrotic repair after acute myocardial infarction.

Read the detailed description

This study will enroll 50 patients with ST-segment elevation myocardial infarction (STEMI). Peripheral blood will be collected from these patients for immune cell subset analysis, serum cytokine evaluation, and neutrophil sorting for transcriptome sequencing. At 1 week after admission, cardiac magnetic resonance (CMR) will be performed to evaluate the myocardial salvage index, area of late gadolinium enhancement (LGE), microvascular obstruction (MVO), extracellular volume (ECV), and left ventricular ejection fraction (LVEF).

02

Conditions studied

  • Myocardial Infarction

Keywords

  • neutrophil
  • monocyte
  • myocardial infarction
  • cardiac remodeling
  • cardiac magnetic resonance
03

In context

Myocardial Infarction

2,270 studies on the registry are indexed under Myocardial Infarction; 371 are open to participants now.

This study's planned enrollment of 50 is below the median of 568 across 814 observational studies indexed under Myocardial Infarction.

Browse Myocardial Infarction studies →

Lead sponsor

Shanghai 10th People's Hospital is the lead sponsor of 167 studies on the registry; 45 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

STEMI patients undergoing PPCI

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

---- Age > 18 and ≤ 80 years old

- Patients with acute STEMI within 12 hours of symptom onset who are planned to receive PPCI

Exclusion criteria

Exclusion Criteria:

  • Prior revascularization
  • Known allergy to gadopentetate dimeglumine contrast agent
  • Pregnancy or planned pregnancy within the next 6 months
  • \< 1 year
  • Metallic implants or claustrophobia that precluded MRI
  • Severe or inability to hold breath for MRI
  • Severe hepatic or renal dysfunction ( > 5× or \< 15 mL/min/1.73 m²)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • STEMI patients

    Patients with acute STEMI within 12 hours of symptom onset receive primary percutaneous coronary intervention.

06

What researchers measure

Primary outcomes

  1. Major cardiac adverse outcome

    The composite endpoint included cardiac death, non-fatal myocardial infarction, and rehospitalization for angina.

    Time frame: At 12 months after enrollment

Secondary outcomes

  1. Cardiac remodeling measured by CMR

    CMR will be performed to evaluate the cardiac fibrosis defined as area of late gadolinium enhancement (LGE).

    Time frame: At 1 week after admission

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — We need preparation.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07764588
Responsible party
Yi Zhang, MD, PhD (Consultant, Shanghai 10th People's Hospital) — Principal investigator
First posted
Aug 14, 2026
Start date
Jan 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 14, 2026

Study contacts

Jianhui Zhuang, MD
Contact
jh_zhuang@tongji.edu.cn
86-13621742833

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion